resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry
“We are pleased to welcome Erkan to resTORbio, as we continue to expand our team in anticipation of building out our pipeline of novel therapeutics for the treatment of aging-related diseases,” said
Dr. Baloglu brings to resTORbio over 18 years of expertise in drug discovery, successfully leading programs from early discovery through the investigational new drug (IND) filing process, and Phase 1 clinical trials. He most recently served as the Executive Director of Discovery and Product Leadership at
“In recent years, there has been substantial advancement in our understanding of biological mechanisms that regulate aging, including TORC1 inhibition, which plays a role in extending healthy lifespan and improving the function of aging organ systems,” said Dr. Baloglu. “I look forward to leading resTORbio’s drug discovery effort, and to translating this growing body of research into new therapies for aging-related diseases.”
resTORbio, Inc. is a clinical stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases. resTORbio’s lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems. Learn more about resTORbio at www.restorbio.com.
Forward Looking Statements:
This press release contains forward-looking statements of resTORbio, Inc. (the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding our growth as a company and the anticipated contribution of our executives to our operations and progress, our plans to develop and commercialize RTB101 alone or in combination with everolimus or sirolimus, including the therapeutic potential and clinical benefits thereof and the potential patient populations that may be addressed by our product candidates, and our ability to replicate results achieved in our clinical trials in any future trials, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the delay of any planned clinical trials and/or development of RTB101, either alone or in combination with everolimus or sirolimus; our ability to successfully demonstrate the efficacy and safety of our lead product candidate; the clinical results for our lead product candidate which may not support further development of additional indications; and obtaining, maintaining and protecting our intellectual property; as well as those risks more fully discussed in the section entitled “Risk Factors” in the Annual Report on Form 10-K filed by resTORbio, Inc. with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing its views as of any subsequent date. resTORbio explicitly disclaims any obligation to update any forward-looking statements.